The novalung iLA, i-cor and medos products offer the full range of pulmonary and cardiac support on the basis of the unique XENIOS platform. The novalung iLA therapy can replace or complement harmful and immobilizing respiration treatments. The i-cor therapy supports cardiac function with a pulse that is synchronous with the human heartbeat. These minimally invasive therapies make it possible to provide cardiac and pulmonary support to patients who are awake, able to function on their own, and mobile. In addition, these therapies make it possible to avoid both damage to and infections in the lungs caused by artificial respiration, and the atrophy of the respiratory musculature.